The fear of a trade war over pharmaceuticals between the EU and the US has been avoided for now, but the European Commission remains on guard, considering further tariff deployments likely.

Roni Kamhi, CEO BI Sky Global and COO of Innocan Pharma commented: "We are very pleased with our outstanding results and especially our strong revenue growth. At BI Sky Global we are clearly ...

RBC Capital analyst Luca Issi maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) on April 3 and set a price target of $330.00. The company’s shares closed yesterday at $235.74.

Zealand Pharma (ZLDPF) announced that the last participant has been enrolled and randomized to active treatment or placebo in ZUPREME-1, a global Phase 2b trial in people with obesity or ...

Governments and employers worldwide have expanded access to care. Yet pharmaceutical innovation hasn’t kept pace. Since the blockbuster success of drugs such as Prozac and Zoloft in the 1990s ...

BERLIN, March 28, 2025--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment ...

Purdue Pharma has filed a new bankruptcy plan as part of a $7.4 billion settlement to resolve thousands of lawsuits over the company’s alleged role in the opioid crisis, months after the Supreme ...

It demands significant resources that are often expensive and inaccessible to biotechnology and pharmaceutical companies of all sizes. Federal regulations like the Current Good Manufacturing ...

President Trump wants to bring pharmaceutical manufacturing back to the United States. Experts warn that tariffs could result in shortages and higher prices for generic drugs. By Rebecca Robbins ...

My wife and I would both be dead, but for what many derisively call “Big Pharma.” My wife has a rare, genetic form of stage four lung cancer for which there is no cure. Her lungs are filled ...

I write about Asia's richest, fast-growing businesses, and startups. Sun Pharmaceutical Industries—controlled by Indian billionaire Dilip Shanghvi—has agreed to buy U.S.-based immunotherapy ...

Previously at the epicenter of the U.S. opioid crisis, Purdue Pharma is looking to reenter the public lexicon as a new public benefit company. After a prior bankruptcy settlement was nixed by the ...